BrainsWay’s Deep TMS pilot study recorded an 83.3% response rate and a 50% remission rate for depressive symptoms in patients with early-stage Alzheimer’s disease. The results matter to investors because the therapy is not FDA-cleared for Alzheimer’s, and the company says controlled clinical research is required to assess the preliminary findings.
Key Highlights
- The peer-reviewed study was published in the Journal of Geriatric Psychiatry and Neurology.
- Researchers used BrainsWay’s H1 and H7 Coils to stimulate prefrontal and temporal brain regions.
- Deep TMS is not FDA-cleared for treating Alzheimer’s disease, according to the release.
Deep TMS Study Records Depression Outcomes
The results included measurable changes in brain activity and connectivity. Treatment used the company’s H1 Coil on the left dorsolateral prefrontal cortex, followed by the H7 Coil on temporal regions. Researchers assessed brain activity with quantitative electroencephalography before and after treatment. The study found reduced delta-band power in the right temporal lobe, alongside increased Alpha coherence between several frontal and temporal sites.
Alzheimer’s Use Still Requires Controlled Research
Remission required a Patient Health Questionnaire-9 score of 4 or less. Deep TMS is not FDA-cleared for treating Alzheimer’s disease. BrainsWay (NASDAQ: BWAY) said the preliminary findings require further evaluation through controlled clinical research.
FAQs
Q: What does the BrainsWay study mean for BWAY investors?
A: The results provide preliminary clinical data for Deep TMS in a complex patient group. The technology is not FDA-cleared for Alzheimer’s disease, and controlled research remains necessary.
Q: Was BrainsWay Deep TMS cleared for Alzheimer’s treatment?
A: No. The release states that Deep TMS is not FDA-cleared for Alzheimer’s disease, while further controlled clinical research is required to evaluate the pilot findings.
Q: How many patients participated in the pilot study, and what treatment did they receive?
A: The pilot study included 12 patients who received 36 Deep TMS sessions. Treatment used the H1 Coil on the left dorsolateral prefrontal cortex and the H7 Coil on temporal regions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.